Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

Transcarent CEO Glen Tullman previously led Livongo, which was purchased by Teladoc in a 2020 agreement that valued the ...

In a report released today, Charles Rhyee from TD Cowen reiterated a Buy rating on CVS Health ( CVS – Research Report ), with a price target of $80.00. The company’s shares closed today at $63.85.

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

After CMS excluded a Biden administration proposal for CMS to cover anti-obesity medications proposal from the final contract year 2026 ...

The Trump administration has declined to cover expensive, high-demand obesity treatments under the federal government’s Medicare program, Tom ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...